{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Hiremath CS"],"pubmed_abstract":["<h4>Objectives</h4>The durability and performance of bioprosthetic valves are pivotal in managing valvular heart disease (VHD). This 5-year follow-up study evaluated the long-term clinical safety, haemodynamic performance, and quality-of-life (QoL) outcomes of the Dafodil™ pericardial bioprosthesis in patients undergoing aortic or mitral valve replacement (AVR/MVR).<h4>Methods</h4>In this prospective, multicenter, first-in-human trial conducted across 19 Indian centers, 136 patients with advanced VHD (67 AVR, 69 MVR) were enrolled. Key endpoints were evaluated over 5 years.<h4>Results</h4>The mean age of the patients in the AVR and MVR cohorts was 60.2 ± 8.3 years and 49.7 ± 14.4 years, respectively. A total of 124 patients (61 AVR, 63 MVR) completed the 5-year follow-up. In the AVR cohort"],"journal":["Frontiers in cardiovascular medicine"],"pagination":["1672315"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12828671"],"repository":["biostudies-literature"],"pubmed_title":["Outcomes of aortic and mitral valve replacement with Dafodil™ pericardial bioprosthesis over 5-years: Dafodil™-1 trial."],"pmcid":["PMC12828671"],"pubmed_authors":["S J C","Garg A","Grover V","Porwal M","Sethuratnam R","Bhat S","Thakur NT","Chaudhary SK","Shastri N","Jain A","Sancheti A","Hiremath CS","Mishra YK","Rajput SS","Padmanabhan C","Sarkar BK","Naik D","Gupta N","Vaijyanath P","Gupta VK","Maslekar A","Singh Meharwal Z"],"additional_accession":[]},"is_claimable":false,"name":"Outcomes of aortic and mitral valve replacement with Dafodil™ pericardial bioprosthesis over 5-years: Dafodil™-1 trial.","description":"<h4>Objectives</h4>The durability and performance of bioprosthetic valves are pivotal in managing valvular heart disease (VHD). This 5-year follow-up study evaluated the long-term clinical safety, haemodynamic performance, and quality-of-life (QoL) outcomes of the Dafodil™ pericardial bioprosthesis in patients undergoing aortic or mitral valve replacement (AVR/MVR).<h4>Methods</h4>In this prospective, multicenter, first-in-human trial conducted across 19 Indian centers, 136 patients with advanced VHD (67 AVR, 69 MVR) were enrolled. Key endpoints were evaluated over 5 years.<h4>Results</h4>The mean age of the patients in the AVR and MVR cohorts was 60.2 ± 8.3 years and 49.7 ± 14.4 years, respectively. A total of 124 patients (61 AVR, 63 MVR) completed the 5-year follow-up. In the AVR cohort","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025","modification":"2026-06-13T05:17:23.548Z","creation":"2026-06-13T03:08:53.62Z"},"accession":"S-EPMC12828671","cross_references":{"pubmed":["41584284"],"doi":["10.3389/fcvm.2025.1672315"]}}